Crinetics Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Crinetics Pharmaceuticals, Inc. (CRNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-26
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.40%, a 4.76% increase year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-09-30 was 3.90%, a 9.30% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-06-30 was 4.50%, a 25.00% increase year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.20%, a 0.00% change year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.30%, a 2.38% increase from fiscal 2024.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 2.44% increase from fiscal 2023.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.10%, a 46.43% increase from fiscal 2022.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.80%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.30% 10-K · filed 2026-02-26 | |||
| 2025-03-31 | 4.40% 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | 4.20% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 3.90% 10-Q · filed 2024-11-12 | 4.20% 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 4.50% 10-Q · filed 2024-08-08 | 4.30% 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 4.20% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 4.10% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 4.30% 10-Q · filed 2024-11-12 | 4.10% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 3.60% 10-Q · filed 2024-08-08 | 4.00% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 4.20% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 2.80% 10-K · filed 2025-02-27 | |||
| 2018-09-30 | 2.80% 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | 2.80% 10-Q · filed 2018-08-30 | |||
| 2017-09-30 | 1.90% 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | 1.90% 10-Q · filed 2018-08-30 |